Navigation Links
Hypogonadism in Medical Technology

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... in Europe and other territories. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ... impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile ...

Indevus Announces Submission of New Drug Application

... reported were comparable to other injectable hypogonadism treatments reported in the literature. There were ... Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical ...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

... 40-69 years, it is estimated that there are about 481,000 new cases of hypogonadism per year. Overall, approximately 2.4 million U.S. men suffer from the condition.(1) hypogonadism results from a deficiency in testosterone secretion that may occur ...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

... previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated ... Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced ...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. ...

QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

... endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial ...

QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

... replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone ...

QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome

... programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. ...

QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome

... programs. Fispemifene is a new, selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. ...

Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

... endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial ...

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

... or hypothalamic dysfunction, when diagnosing hypogonadism in men." Although the syndrome of secondary hypogonadism is characterized by the objective measurements of ... potential to change the way in which secondary hypogonadism is treated in the future." Repros anticipates ...

Indevus Reports Positive Data From Phase III NEBIDO Trial

... under development for the treatment of male hypogonadism which the Company licensed from Bayer Schering ... Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

... of their current relationship. About hypogonadism (Low Testosterone) Physical signs of hypogonadism can include incomplete sexual development, body ... sperm production. Symptoms associated with hypogonadism can include reduced sexual desire, depression, ...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

... an initial inadequate response. About hypogonadism Low testosterone ("Low T"), or hypogonadism, is ... testosterone production. Physical signs of hypogonadism can include incomplete sexual development, body ... a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and ...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

... (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT(R) (testosterone buccal system) for the treatment of hypogonadism in men. For more information, please visit www.columbialabs.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: ...

Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

... orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. AA4500, an injectable collagenase ...
Other Contents
(Date:7/27/2014)... of "big data," a single computer cannot always find ... be distributed across a cluster of computers that analyze ... Google mine your web history to present you with ... next favorite book or movie. But big data is ... for monitoring brain activity are generating unprecedented quantities of ...
(Date:7/25/2014)... on the land now called California, and many of ... plants they used for food, fuel, tools, and ritual. ... habitat and natural resources. , Frank Lake, an ecologist ... lead a field trip to the Stone ... America,s 99th Annual Meeting, in Sacramento, Cal. this August. ...
(Date:7/25/2014)... (July 24, 2014)The link between autism and disrupted ... puzzle of the disease, and is largely unknown. ... Autism Research Initiative (SFARI), George Washington University (GW) ... offer truly integrative and in-depth answers to these ... , LaMantia, professor of pharmacology and physiology ...
Breaking Biology News(10 mins):New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3GW researcher receives grant to answer the how and why of autism during development 2
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... The constant expansion of companies across the globe has ... Additional factors that have increased this demand include the ... communication, learning and development, security and safety, and knowledge ... enterprise video market value has crossed $11.21 billion in ... 2018 with a compound annual growth rate (CAGR) of ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market ... Type (OE & Aftermarket), Filter Type (Oil & Fuel), ... Trends & Forecast to 2018”, defines and segments the ... and forecasting of the global volume and revenue. The ... a revenue of $6.1 billion in 2018, while fuel ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European Bromine ... with analysis and forecast of revenue. , Bromine market in ... France, Spain, and UK. Germany and France that forms a ... and its derivatives in Europe. , Browse through the ... idea of the in-depth analysis provided Browse through the TOC ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
Other TagsOther Tags